Compile Data Set for Download or QSAR
Report error Found 87 Enz. Inhib. hit(s) with all data for entry = 50018048
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataIC50: 0.660nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataIC50: 0.660nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417023((+)-N-(5-(1-amino-1-(4-carbamoylphenyl)-3-cyclopro...)
Affinity DataIC50: 0.900nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416897(US10329260, Compound 58c | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50607250(CHEMBL5219146)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50607250(CHEMBL5219146)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416946((+-)-1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416996((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416996((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416774(US10329260, Compound 92g | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417014((+-)-N-(5-(1-amino-1-(3-carbamoylphenyl)-3-cyclopr...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417024((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417024((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416770(US10329260, Compound 47f | Racemic 1-(3-(aminometh...)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataIC50: 2.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417008((+)-N-(5-(1-amino-1-(6-cyanopyridin-2-yl)-3-cyclop...)
Affinity DataIC50: 2.90nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417024((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataIC50: 3nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417024((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataIC50: 3nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50: 3nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416909(US10329260, Compound 59c | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 3nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416996((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416996((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416938((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataIC50: 3.60nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416897(US10329260, Compound 58c | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 3.60nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416897(US10329260, Compound 58c | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 3.60nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417023((+)-N-(5-(1-amino-1-(4-carbamoylphenyl)-3-cyclopro...)
Affinity DataIC50: 3.80nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416774(US10329260, Compound 92g | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 4.70nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416774(US10329260, Compound 92g | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 4.70nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416938((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataIC50: 5nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416938((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataIC50: 5nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataIC50: 5.40nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416770(US10329260, Compound 47f | Racemic 1-(3-(aminometh...)
Affinity DataIC50: 5.70nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416770(US10329260, Compound 47f | Racemic 1-(3-(aminometh...)
Affinity DataIC50: 5.70nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417014((+-)-N-(5-(1-amino-1-(3-carbamoylphenyl)-3-cyclopr...)
Affinity DataIC50: 6nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataIC50: 7nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataIC50: 7nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416774(US10329260, Compound 92g | 1-(3-(aminomethyl)pheny...)
Affinity DataIC50: 7.60nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50607250(CHEMBL5219146)
Affinity DataIC50: 7.70nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50607250(CHEMBL5219146)
Affinity DataIC50: 7.70nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 8nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataIC50: 8nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
Displayed 1 to 50 (of 87 total ) | Next | Last >>
Jump to: